ID   PGFRA_HUMAN             Reviewed;        1089 AA.
AC   P16234; B2RE69; Q96KZ7; Q9UD28;
DT   01-APR-1990, integrated into UniProtKB/Swiss-Prot.
DT   01-APR-1990, sequence version 1.
DT   02-NOV-2010, entry version 127.
DE   RecName: Full=Alpha-type platelet-derived growth factor receptor;
DE            Short=PDGF-R-alpha;
DE            EC=2.7.10.1;
DE   AltName: Full=CD140 antigen-like family member A;
DE   AltName: Full=CD140a antigen;
DE   AltName: CD_antigen=CD140a;
DE   Flags: Precursor;
GN   Name=PDGFRA;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Foreskin;
RX   MEDLINE=89296915; PubMed=2544881; DOI=10.1073/pnas.86.13.4917;
RA   Claesson-Welsh L., Eriksson A., Westermark B., Heldin C.H.;
RT   "cDNA cloning and expression of the human A-type platelet-derived
RT   growth factor (PDGF) receptor establishes structural similarity to the
RT   B-type PDGF receptor.";
RL   Proc. Natl. Acad. Sci. U.S.A. 86:4917-4921(1989).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   MEDLINE=89130149; PubMed=2536956; DOI=10.1126/science.2536956;
RA   Matsui T., Heidaran M., Miki T., Popescu N., la Rochelle W., Kraus M.,
RA   Pierce J., Aaronson S.;
RT   "Isolation of a novel receptor cDNA establishes the existence of two
RT   PDGF receptor genes.";
RL   Science 243:800-804(1989).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   TISSUE=Blood;
RX   MEDLINE=96163874; PubMed=8586421; DOI=10.1006/geno.1995.9883;
RA   Kawagishi J., Ku T.;
RT   "Structure, organization, and transcription units of the human alpha-
RT   platelet-derived growth factor receptor gene, PDGFRA.";
RL   Genomics 30:224-232(1995).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT
RP   PRO-478.
RC   TISSUE=Trachea;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 579-1089, DISEASE, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY OF FIP1L1-PDGFRA FUSION PROTEIN.
RC   TISSUE=Eosinophil;
RX   PubMed=12808148; DOI=10.1073/pnas.0932698100;
RA   Griffin J.H., Leung J., Bruner R.J., Caligiuri M.A., Briesewitz R.;
RT   "Discovery of a fusion kinase in EOL-1 cells and idiopathic
RT   hypereosinophilic syndrome.";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:7830-7835(2003).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 823-876, AND TISSUE SPECIFICITY.
RC   TISSUE=Colon tumor;
RX   MEDLINE=95204052; PubMed=7896447; DOI=10.1002/ijc.2910600611;
RA   Craven R.J., Xu L.H., Weiner T.M., Fridell Y.-W., Dent G.A.,
RA   Srivastava S., Varnum B., Liu E.T., Cance W.G.;
RT   "Receptor tyrosine kinases expressed in metastatic colon cancer.";
RL   Int. J. Cancer 60:791-797(1995).
RN   [8]
RP   INTERACTION WITH SHF, AND PROBABLE PHOSPHORYLATION AT TYR-720.
RX   MEDLINE=20548990; PubMed=11095946; DOI=10.1006/bbrc.2000.3847;
RA   Lindholm C.K., Frantz J.D., Shoelson S.E., Welsh M.;
RT   "Shf, a Shb-like adapter protein, is involved in PDGF-alpha-receptor
RT   regulation of apoptosis.";
RL   Biochem. Biophys. Res. Commun. 278:537-543(2000).
RN   [9]
RP   INVOLVEMENT IN HES.
RX   MEDLINE=22547205; PubMed=12660384; DOI=10.1056/NEJMoa025217;
RA   Cools J., DeAngelo D.J., Gotlib J., Stover E.H., Legare R.D.,
RA   Cortes J., Kutok J., Clark J., Galinsky I., Griffin J.D., Cross N.C.,
RA   Tefferi A., Malone J., Alam R., Schrier S.L., Schmid J., Rose M.,
RA   Vandenberghe P., Verhoef G., Boogaerts M., Wlodarska I.,
RA   Kantarjian H., Marynen P., Coutre S.E., Stone R., Gilliland D.G.;
RT   "A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as
RT   a therapeutic target of imatinib in idiopathic hypereosinophilic
RT   syndrome.";
RL   N. Engl. J. Med. 348:1201-1214(2003).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-762; TYR-768; TYR-849
RP   AND TYR-1018, AND MASS SPECTROMETRY.
RC   TISSUE=Lung carcinoma;
RX   PubMed=18083107; DOI=10.1016/j.cell.2007.11.025;
RA   Rikova K., Guo A., Zeng Q., Possemato A., Yu J., Haack H., Nardone J.,
RA   Lee K., Reeves C., Li Y., Hu Y., Tan Z., Stokes M., Sullivan L.,
RA   Mitchell J., Wetzel R., Macneill J., Ren J.M., Yuan J.,
RA   Bakalarski C.E., Villen J., Kornhauser J.M., Smith B., Li D., Zhou X.,
RA   Gygi S.P., Gu T.-L., Polakiewicz R.D., Rush J., Comb M.J.;
RT   "Global survey of phosphotyrosine signaling identifies oncogenic
RT   kinases in lung cancer.";
RL   Cell 131:1190-1203(2007).
RN   [11]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 1185-1189 IN COMPLEX WITH
RP   SLC9A3R1 AND PDGFRB.
RX   MEDLINE=22013966; PubMed=11882663; DOI=10.1074/jbc.M201507200;
RA   Karthikeyan S., Leung T., Ladias J.A.A.;
RT   "Structural determinants of the Na+/H+ exchanger regulatory factor
RT   interaction with the beta 2 adrenergic and platelet-derived growth
RT   factor receptors.";
RL   J. Biol. Chem. 277:18973-18978(2002).
RN   [12]
RP   VARIANTS [LARGE SCALE ANALYSIS] ASP-79; ASP-426; PRO-478; CYS-764;
RP   ARG-829; LYS-996 AND ASN-1071.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Receptor that binds both PDGFA and PDGFB and has a
CC       tyrosine-protein kinase activity.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate.
CC   -!- SUBUNIT: Homodimer, and heterodimer with PDGFRB. Interacts with
CC       the SH2 domain of SHB via phosphorylated Tyr-720 (By similarity).
CC       Interacts with the SH2 domain of SHF via phosphorylated Tyr-720.
CC   -!- SUBCELLULAR LOCATION: Membrane; Single-pass type I membrane
CC       protein.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P16234-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P16234-2; Sequence=VSP_007833, VSP_007834;
CC         Note=No experimental confirmation available;
CC   -!- TISSUE SPECIFICITY: Expressed in primary and metastatic colon
CC       tumors and in normal colon tissue. Tumors may express a different
CC       isoform to that found in normal tissue.
CC   -!- DISEASE: A fusion of PDGFRA and FIP1L1 (FIP1L1-PDGFRA), due to an
CC       interstitial chromosomal deletion, is the cause of some cases of
CC       hypereosinophilic syndrome (HES) [MIM:607685]. HES is a rare
CC       hematologic disorder characterized by sustained overproduction of
CC       eosinophils in the bone marrow, eosinophilia, tissue infiltration
CC       and organ damage.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. CSF-1/PDGF receptor subfamily.
CC   -!- SIMILARITY: Contains 5 Ig-like C2-type (immunoglobulin-like)
CC       domains.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAP69563.1; Type=Erroneous initiation;
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M22734; AAA60048.1; -; mRNA.
DR   EMBL; M21574; AAA96715.1; -; mRNA.
DR   EMBL; D50017; BAA08742.1; -; Genomic_DNA.
DR   EMBL; AK316578; BAG38166.1; -; mRNA.
DR   EMBL; BC015186; AAH15186.1; -; mRNA.
DR   EMBL; AY229892; AAP69563.1; ALT_INIT; mRNA.
DR   IPI; IPI00027721; -.
DR   IPI; IPI00336178; -.
DR   PIR; A40162; PFHUGA.
DR   RefSeq; NP_006197.1; -.
DR   UniGene; Hs.74615; -.
DR   PDB; 1GQ5; X-ray; 2.20 A; -.
DR   PDBsum; 1GQ5; -.
DR   ProteinModelPortal; P16234; -.
DR   SMR; P16234; 25-513, 551-694, 571-947, 787-951.
DR   DIP; DIP-5736N; -.
DR   IntAct; P16234; 1.
DR   STRING; P16234; -.
DR   PhosphoSite; P16234; -.
DR   PRIDE; P16234; -.
DR   Ensembl; ENST00000257290; ENSP00000257290; ENSG00000134853.
DR   GeneID; 5156; -.
DR   KEGG; hsa:5156; -.
DR   UCSC; uc003hal.2; human.
DR   UCSC; uc003han.2; human.
DR   CTD; 5156; -.
DR   GeneCards; GC04P055095; -.
DR   H-InvDB; HIX0004218; -.
DR   HGNC; HGNC:8803; PDGFRA.
DR   HPA; CAB018143; -.
DR   MIM; 173490; gene.
DR   MIM; 607685; phenotype.
DR   Orphanet; 513; Acute lymphoblastic leukemia.
DR   Orphanet; 44890; Gastrointestinal stromal tumor.
DR   Orphanet; 168956; Hypereosinophilic syndromes.
DR   Orphanet; 168947; Myeloid neoplasm associated with PDGFRA rearrangement.
DR   PharmGKB; PA33147; -.
DR   eggNOG; prNOG04413; -.
DR   HOGENOM; HBG445154; -.
DR   HOVERGEN; HBG004335; -.
DR   InParanoid; P16234; -.
DR   OMA; YIGVTYK; -.
DR   OrthoDB; EOG98SKD5; -.
DR   PhylomeDB; P16234; -.
DR   BRENDA; 2.7.10.1; 247.
DR   Pathway_Interaction_DB; pdgfrapathway; PDGFR-alpha signaling pathway.
DR   Reactome; REACT_16888; Signaling by PDGF.
DR   DrugBank; DB00102; Becaplermin.
DR   DrugBank; DB00619; Imatinib.
DR   DrugBank; DB01268; Sunitinib.
DR   NextBio; 19946; -.
DR   ArrayExpress; P16234; -.
DR   Bgee; P16234; -.
DR   CleanEx; HS_PDGFRA; -.
DR   Genevestigator; P16234; -.
DR   GermOnline; ENSG00000134853; Homo sapiens.
DR   GO; GO:0005887; C:integral to plasma membrane; IDA:BHF-UCL.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0005018; F:platelet-derived growth factor alpha-recept...; IDA:BHF-UCL.
DR   GO; GO:0048407; F:platelet-derived growth factor binding; IPI:BHF-UCL.
DR   GO; GO:0005161; F:platelet-derived growth factor receptor bin...; IPI:BHF-UCL.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:BHF-UCL.
DR   GO; GO:0005021; F:vascular endothelial growth factor receptor...; IDA:BHF-UCL.
DR   GO; GO:0001775; P:cell activation; TAS:BHF-UCL.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0030335; P:positive regulation of cell migration; IDA:BHF-UCL.
DR   GO; GO:0045740; P:positive regulation of DNA replication; IDA:BHF-UCL.
DR   GO; GO:0048146; P:positive regulation of fibroblast prolifera...; IDA:BHF-UCL.
DR   GO; GO:0046777; P:protein amino acid autophosphorylation; IDA:BHF-UCL.
DR   InterPro; IPR007110; Ig-like.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR013098; Ig_I-set.
DR   InterPro; IPR003599; Ig_sub.
DR   InterPro; IPR003598; Ig_sub2.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_cat_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr-Pkinase.
DR   InterPro; IPR020635; Tyr_Pkinase_cat_dom.
DR   InterPro; IPR020685; Tyr_prot_kinase.
DR   InterPro; IPR008266; Tyr_prot_kinase_AS.
DR   InterPro; IPR016243; Tyr_prot_kinase_CSF1/PDGF_rcpt.
DR   InterPro; IPR015776; Tyr_prot_kinase_PDGF_rcpt_a.
DR   InterPro; IPR001824; Tyr_prot_kinase_rcpt_3_CS.
DR   InterPro; IPR009134; Tyr_prot_kinase_VEGFR_rcpt_N.
DR   Gene3D; G3DSA:2.60.40.10; Ig-like_fold; 5.
DR   PANTHER; PTHR23256:SF207; PDGFR_alpha; 1.
DR   PANTHER; PTHR23256; Tyr_prot_kinase; 1.
DR   Pfam; PF07679; I-set; 2.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   PIRSF; PIRSF000615; TyrPK_CSF1-R; 1.
DR   PRINTS; PR01832; VEGFRECEPTOR.
DR   SMART; SM00409; IG; 2.
DR   SMART; SM00408; IGc2; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF56112; Kinase_like; 1.
DR   PROSITE; PS50835; IG_LIKE; 2.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS00240; RECEPTOR_TYR_KIN_III; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Complete proteome;
KW   Disulfide bond; Glycoprotein; Immunoglobulin domain; Kinase; Membrane;
KW   Nucleotide-binding; Phosphoprotein; Polymorphism; Receptor; Repeat;
KW   Signal; Transferase; Transmembrane; Transmembrane helix;
KW   Tyrosine-protein kinase.
FT   SIGNAL        1     23
FT   CHAIN        24   1089       Alpha-type platelet-derived growth factor
FT                                receptor.
FT                                /FTId=PRO_0000016760.
FT   TOPO_DOM     24    524       Extracellular (Potential).
FT   TRANSMEM    525    549       Helical; (Potential).
FT   TOPO_DOM    550   1089       Cytoplasmic (Potential).
FT   DOMAIN       24    113       Ig-like C2-type 1.
FT   DOMAIN      117    201       Ig-like C2-type 2.
FT   DOMAIN      202    306       Ig-like C2-type 3.
FT   DOMAIN      319    410       Ig-like C2-type 4.
FT   DOMAIN      414    517       Ig-like C2-type 5.
FT   DOMAIN      593    954       Protein kinase.
FT   NP_BIND     599    607       ATP (By similarity).
FT   COMPBIAS   1041   1087       Ser-rich.
FT   ACT_SITE    818    818       Proton acceptor (By similarity).
FT   BINDING     627    627       ATP (By similarity).
FT   SITE        578    579       Breakpoint for interstitial deletion to
FT                                form the FIP1L1-PDGFRA fusion protein.
FT   MOD_RES     720    720       Phosphotyrosine (Probable).
FT   MOD_RES     762    762       Phosphotyrosine.
FT   MOD_RES     768    768       Phosphotyrosine.
FT   MOD_RES     849    849       Phosphotyrosine; by autocatalysis (By
FT                                similarity).
FT   MOD_RES    1018   1018       Phosphotyrosine.
FT   CARBOHYD     42     42       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD     76     76       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    103    103       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    179    179       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    353    353       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    359    359       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    458    458       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    468    468       N-linked (GlcNAc...) (Potential).
FT   DISULFID     49    100       By similarity.
FT   DISULFID    150    189       By similarity.
FT   DISULFID    235    290       By similarity.
FT   DISULFID    435    501       By similarity.
FT   VAR_SEQ     210    218       ATSELDLEM -> GTCIISFLL (in isoform 2).
FT                                /FTId=VSP_007833.
FT   VAR_SEQ     219   1089       Missing (in isoform 2).
FT                                /FTId=VSP_007834.
FT   VARIANT      79     79       G -> D (in dbSNP:rs36035373).
FT                                /FTId=VAR_042032.
FT   VARIANT     426    426       G -> D (in dbSNP:rs55865821).
FT                                /FTId=VAR_042033.
FT   VARIANT     478    478       S -> P (in dbSNP:rs35597368).
FT                                /FTId=VAR_034378.
FT   VARIANT     764    764       R -> C (in dbSNP:rs34392012).
FT                                /FTId=VAR_042034.
FT   VARIANT     829    829       G -> R (in a glioblastoma multiforme
FT                                sample; somatic mutation).
FT                                /FTId=VAR_042035.
FT   VARIANT     996    996       E -> K (in a metastatic melanoma sample;
FT                                somatic mutation).
FT                                /FTId=VAR_042036.
FT   VARIANT    1071   1071       D -> N (in a lung neuroendocrine
FT                                carcinoma sample; somatic mutation).
FT                                /FTId=VAR_042037.
SQ   SEQUENCE   1089 AA;  122670 MW;  5E3FB9940ACD1BE8 CRC64;
     MGTSHPAFLV LGCLLTGLSL ILCQLSLPSI LPNENEKVVQ LNSSFSLRCF GESEVSWQYP
     MSEEESSDVE IRNEENNSGL FVTVLEVSSA SAAHTGLYTC YYNHTQTEEN ELEGRHIYIY
     VPDPDVAFVP LGMTDYLVIV EDDDSAIIPC RTTDPETPVT LHNSEGVVPA SYDSRQGFNG
     TFTVGPYICE ATVKGKKFQT IPFNVYALKA TSELDLEMEA LKTVYKSGET IVVTCAVFNN
     EVVDLQWTYP GEVKGKGITM LEEIKVPSIK LVYTLTVPEA TVKDSGDYEC AARQATREVK
     EMKKVTISVH EKGFIEIKPT FSQLEAVNLH EVKHFVVEVR AYPPPRISWL KNNLTLIENL
     TEITTDVEKI QEIRYRSKLK LIRAKEEDSG HYTIVAQNED AVKSYTFELL TQVPSSILDL
     VDDHHGSTGG QTVRCTAEGT PLPDIEWMIC KDIKKCNNET SWTILANNVS NIITEIHSRD
     RSTVEGRVTF AKVEETIAVR CLAKNLLGAE NRELKLVAPT LRSELTVAAA VLVLLVIVII
     SLIVLVVIWK QKPRYEIRWR VIESISPDGH EYIYVDPMQL PYDSRWEFPR DGLVLGRVLG
     SGAFGKVVEG TAYGLSRSQP VMKVAVKMLK PTARSSEKQA LMSELKIMTH LGPHLNIVNL
     LGACTKSGPI YIITEYCFYG DLVNYLHKNR DSFLSHHPEK PKKELDIFGL NPADESTRSY
     VILSFENNGD YMDMKQADTT QYVPMLERKE VSKYSDIQRS LYDRPASYKK KSMLDSEVKN
     LLSDDNSEGL TLLDLLSFTY QVARGMEFLA SKNCVHRDLA ARNVLLAQGK IVKICDFGLA
     RDIMHDSNYV SKGSTFLPVK WMAPESIFDN LYTTLSDVWS YGILLWEIFS LGGTPYPGMM
     VDSTFYNKIK SGYRMAKPDH ATSEVYEIMV KCWNSEPEKR PSFYHLSEIV ENLLPGQYKK
     SYEKIHLDFL KSDHPAVARM RVDSDNAYIG VTYKNEEDKL KDWEGGLDEQ RLSADSGYII
     PLPDIDPVPE EEDLGKRNRH SSQTSEESAI ETGSSSSTFI KREDETIEDI DMMDDIGIDS
     SDLVEDSFL
//
